Viemed Healthcare, Inc. VMD R2K

Healthcare · Medical Devices · United States

https://www.viemed.com

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

Market & Price

Market Cap

$377.23M

Current Price

$9.84

High / Low (52W)

$10.05 / $5.93

Beta

1.15

Valuation

Stock P/E

26.59

Industry PE

23.65

Forward P/E

24.60

PEG Ratio

Book Value

$3.72

Price to Book

2.64

P/S

1.32

EV/EBITDA

6.99

Dividend Yield

Profitability & Returns

ROCE

14.52%

ROE

10.89%

ROA

8.32%

Profit Margin

5.20%

Op Margin

6.27%

EPS (Latest Qtr)

$0.06

EPS (TTM)

$0.37

Balance Sheet & Liquidity

Debt/Equity

0.09

Quick Ratio

1.01

Current Ratio

1.22

Debt

$12.44M

Total Assets

$199.15M

Current Assets

$48.49M

Working Capital

$7.44M

Ownership

Promoter Holding

13.91%

Chg in Prom Hold

FII / Inst Holding

70.43%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$381.84M

Total Revenue (TTM)

$286.56M

EBITDA

$54.62M

Free Cash Flow

$28.27M

Operating Cash Flow

$57.13M

Shares Outstanding

38.34M

Gross Margin

57.58%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

24.87%

Profit 5Y

33.89%

Revenue (YoY)

27.50%

Earnings (YoY)

0.00%

PROS

Compounding revenue at 24.9% over 5 years.
Profit CAGR of 33.9% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	VMD Viemed Healthcare, Inc. R2K	9.84	26.59	$377.23M	-	14.52%	10.89%	24.87%	33.89%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	13.96M	15.21M	16.93M	18.36M	18.11M	20.32M	20.37M	21.45M	23.81M	42.85M	33.45M	31.20M	28.42M	27.40M	29.29M	32.26M	33.31M	35.76M	39.56M	43.31M	49.40M	50.59M	54.97M	-	-	59.13M	63.06M	71.91M	76.18M	75.41M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.85M	26.32M	30.57M	32.08M	32.59M
Gross Profit	10.40M	11.02M	12.83M	13.52M	13.07M	14.64M	14.05M	14.24M	15.55M	25.93M	19.45M	19.18M	17.74M	17.62M	18.38M	19.74M	20.39M	21.65M	24.00M	26.11M	30.56M	29.80M	32.89M	-	-	33.28M	36.73M	41.34M	44.10M	42.83M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.81M	32.27M	35.23M	35.44M	38.17M
Operating Income	2.34M	2.29M	2.51M	2.92M	2.32M	1.66M	2.19M	2.69M	4.62M	12.86M	4.04M	5.27M	1.33M	2.66M	2.92M	2.25M	1.00M	1.47M	1.93M	2.90M	4.21M	2.20M	3.62M	-	-	1.47M	4.46M	6.12M	8.66M	4.65M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.45M	11.35M	13.18M	15.94M	11.92M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147.00K	179.00K	-	507.00K	364.00K	305.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.66M	4.96M	5.13M	8.01M	3.99M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	952.00K	1.71M	1.53M	2.19M	1.28M
Net Income	2.22M	2.10M	2.22M	2.97M	1.96M	1.33M	2.85M	2.39M	4.24M	19.41M	2.80M	5.07M	1.68M	1.57M	1.79M	1.76M	967.00K	1.05M	1.52M	2.33M	2.92M	1.60M	1.47M	-	-	2.62M	3.16M	3.51M	5.64M	2.58M
Diluted EPS	0.06	0.05	0.06	0.07	0.05	0.03	0.07	0.06	0.11	0.48	0.07	0.12	0.04	0.04	0.04	0.04	0.02	0.03	0.04	0.06	0.07	0.04	0.04	-	-	0.06	0.08	0.09	0.14	0.06
R&D Expense	0	0	0	0	234.00K	203.00K	208.00K	-	174.00K	271.00K	243.00K	-	339.00K	583.00K	576.00K	632.00K	672.00K	670.00K	780.00K	758.00K	593.00K	750.00K	758.00K	757.00K	-	797.00K	847.00K	775.00K	-	579.00K

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	64.46M	80.26M	131.31M	-	138.83M	183.01M	224.26M	270.28M
Cost of Revenue	-	-	-	-	54.15M	70.22M	91.05M	114.82M
Gross Profit	47.77M	56.01M	80.11M	-	84.68M	112.78M	133.20M	155.46M
Operating Expenses	-	-	-	-	76.08M	97.81M	117.21M	134.75M
Operating Income	10.06M	8.86M	26.78M	-	8.60M	14.97M	15.99M	20.71M
EBITDA	-	-	-	-	24.82M	36.68M	42.31M	51.56M
Interest Expense	-	-	-	-	197.00K	424.00K	776.00K	1.18M
Pretax Income	-	-	-	-	8.99M	14.39M	16.17M	21.77M
Tax Provision	-	-	-	-	2.77M	4.15M	4.76M	6.39M
Net Income	9.51M	8.53M	31.53M	-	6.22M	10.24M	11.27M	14.93M
Diluted EPS	0.24	0.21	0.78	0.22	0.16	0.25	0.28	-
R&D Expense	0	848.00K	1.08M	2.11M	2.70M	2.78M	3.07M	3.02M

Compounded Sales Growth

5 Years:	24.87%
1 Year:	27.50%

Compounded Profit Growth

5 Years:	33.89%
1 Year:	0.00%

Stock Price Performance

1 Year:	+47.97%
6 Months:	+39.77%
3 Months:	+13.10%
1 Month:	-0.51%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	40.66M	44.26M	49.24M	53.65M	58.72M	71.01M	79.98M	82.60M	112.56M	-	117.04M	154.90M	177.07M	199.15M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	39.74M	38.37M	52.88M	48.49M
Cash & Equivalents	-	4.63M	8.55M	10.17M	10.41M	7.41M	7.69M	12.63M	13.36M	30.98M	-	16.91M	12.84M	17.54M	13.50M
Inventory	-	-	-	-	-	-	-	-	-	-	-	3.57M	4.63M	4.32M	5.05M
Receivables	-	-	-	-	-	-	-	-	-	-	-	15.38M	18.45M	24.91M	25.59M
Total Liabilities	-	15.92M	16.76M	18.85M	21.08M	24.83M	34.88M	39.66M	38.90M	30.87M	-	19.95M	41.00M	43.77M	55.63M
Current Liabilities	-	14.61M	15.46M	17.19M	19.57M	21.68M	27.39M	26.55M	25.91M	23.02M	-	18.86M	32.12M	37.33M	41.06M
Long Term Debt	-	0	0	0	0	0	4.70M	8.08M	7.63M	5.80M	4.31M	-	6.00M	3.59M	11.29M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	694.00K	10.32M	6.87M	15.95M
Total Equity	21.95M	24.74M	27.50M	30.39M	32.57M	33.89M	36.14M	40.32M	43.70M	81.69M	-	97.09M	113.89M	131.39M	141.54M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	38.05M	38.51M	39.13M	38.02M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	22.37M	19.09M	35.11M	-	27.75M	45.21M	39.09M	51.92M
Investing Cash Flow	-5.30M	-12.81M	-8.41M	-	-23.98M	-52.11M	-30.70M	-50.17M
Financing Cash Flow	-11.75M	-3.33M	-9.07M	-	-15.27M	2.83M	-3.69M	-5.79M
Capital Expenditure	-6.11M	-13.38M	-13.04M	-	-22.90M	-26.09M	-37.77M	-39.98M
Free Cash Flow	16.25M	5.70M	22.07M	-	4.85M	19.12M	1.32M	11.93M
Net Change in Cash	-	-	-	-	-11.49M	-4.08M	4.70M	-4.04M
Share Buybacks	1.59M	1.52M	0	0	9.57M	0	0	13.22M

Ratios (Annual)

Figures in %.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	74.1%	69.8%	61.0%	-	61.0%	61.6%	59.4%	57.5%
Operating Margin %	15.6%	11.0%	20.4%	-	6.2%	8.2%	7.1%	7.7%
Net Margin %	14.7%	10.6%	24.0%	-	4.5%	5.6%	5.0%	5.5%
ROE %	29.2%	19.5%	38.6%	-	6.4%	9.0%	8.6%	10.6%
ROCE %	29.5%	15.6%	29.9%	-	8.8%	12.2%	11.4%	13.1%

Shareholding Pattern

Insiders

13.91%

Institutions

70.43%

Public Float

81.80%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	12.06%	4.62M	$45.49M
2	Forager Capital Management, LLC	7.37%	2.83M	$27.81M
3	Goldman Sachs Group Inc	3.71%	1.42M	$13.99M
4	Vanguard Capital Management LLC	3.40%	1.30M	$12.83M
5	Ameriprise Financial, Inc.	2.34%	898.32K	$8.84M
6	Nantahala Capital Management, LLC	2.31%	883.78K	$8.70M
7	Geode Capital Management, LLC	2.03%	779.52K	$7.67M
8	State Street Corporation	1.94%	742.96K	$7.31M
9	Arrowstreet Capital, Limited Partnership	1.86%	711.19K	$7.00M
10	Punch & Associates Investment Management, Inc.	1.40%	537.36K	$5.29M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VMD

No recent headlines available.

VMD · Healthcare